Navigation Links
Cellectis In-Licenses Induced Pluripotent Stem Cell Technology From iPS Academia Japan
Date:10/18/2010

ation of innovative technologies to deliver robust and high value products," declared David Sourdive, PhD, Executive Vice President, Corporate Development for Cellectis. "This could potentially lead to the development of important new products in the field of human healthcare, which is a long-standing commitment for Cellectis."

"iPS Academia Japan is pleased to build a faithful relationship with Cellectis through these agreements and believe that this will be a significant step for the expansion of iPS cell technology, especially for application of this technology for regenerative medicine, " said Osamu Yoshida, MD, PhD, President and Chief Executive Officer of iPS Academia Japan Inc.

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over euro 70 million in funding since inception.

More information at www.cellectis.com

Follow Cellectis on Twitter at www.twitter.com/cellectis

About Ectycell

Ectycell was established as a subsidiary of Cellectis in September 2009 to research and commercialize industrial uses of stem cells. Its initial goals are to develop tools for generating induced pluripotent stem (iPS) cells from adult c
'/>"/>

SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearchs cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery
2. Cellectis Bioresearch and Cedarlane Join Forces for the Distribution of cGPS® and cGPS® Custom Kits in Canada
3. Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India
4. Cellectis bioresearch Announces Establishment of Subsidiary in the US
5. Cellectis Publishes Its Financial Statement for the First Half of 2010
6. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
7. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
8. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
9. Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice
10. FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
(Date:3/26/2015)... and VANCOUVER, British Columbia, March 26, 2015 /PRNewswire/ ... provided a summary of clinical developments and announced ... Clinical Developments and Anticipated Near-term ... OncoGenex and Teva agreed to negotiate the termination ... OncoGenex. Negotiations of the final termination agreement are ...
(Date:3/26/2015)... S.C. , March 26, 2015 ... told by their existing PACS vendor their system ... (CMH) determined that they needed a better structured ... Hospital selected Avreo interWORKS due to its interface ... modern meaningful use standards through to the hospital,s ...
Breaking Medicine Technology:Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
(Date:3/27/2015)... 27, 2015 When struck with the ... to know where to begin. The latest eBook ... accident attorney, offers accident victims a clear and concise ... to ensure their personal injury claim is seen through ... the first actions that should be taken immediately following ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The ... Industry is a professional and in-depth study on ... market with a focus on the Chinese ... of the industry including definitions, classifications, applications and ... provided for both the international and Chinese domestic ...
(Date:3/27/2015)... RI (PRWEB) March 27, 2015 April 2015 ... war – the Sesquicentennial. To honor America’s bloodiest war and ... Fort Adams Trust presents A Tribute to the Civil War ... PM, Friday, April 17, 2015, at the Jane Pickens Theater ... noted Civil War-Lincoln scholar, will serve as the master of ...
(Date:3/27/2015)... March 27, 2015 The ... Quaker-based, philanthropic, grant-making foundation committed to raising its ... healthcare is delivered. , The Scattergood Foundation and ... Behavioral Health Policy and Practice through the Annual ... Program App is designed to guide the ...
(Date:3/26/2015)... March 26, 2015 Alliance Healthcare Foundation ... and wellness for the poor and underserved in San ... for its annual $1 million award, the Innovation Initiative ... announce the 2015 round of our Innovation Initiative Award,” ... supported some incredibly creative and ambitious projects in the ...
Breaking Medicine News(10 mins):Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 2Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 3Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 4Health News:SoundsLikeIBS Nominated For 3rd Annual Scattergood Innovation Award 2Health News:Applications Open for $1M Innovation Initiative Award from Alliance Healthcare Foundation 2
... Gerresheimer Stock in the SDAX as Per September 6, 2007 ... Outside the Normal Schedule, ... 5 September, DÜSSELDORF, Germany, September 3 Gerresheimer AG has,been listed ... following one of the largest IPOs of the year, with a total,issue ...
... we all know that tall parents are more likely to ... common genes that make people taller than others. Now, however, ... common variant of which directly influences height. , The ... the variant and a person carrying no copies is just ...
... 31, 2007) Two worldwide studies published in this week,s ... chronic obstructive pulmonary disease (COPD). The only U.S. site in ... in Eastern Kentucky, and was found to have some of ... fact, it had the second highest rate among women and ...
... designed for brain tumour therapy has shown promising tumour ... by scientists at The University of Nottingham. The project, ... and Human Development, will be featured in the September ... for brain cancers is particularly difficult for a number ...
... in on diacetyl, a key component of butter flavoring in ... key chemical ingredient in the buttery flavoring of microwave popcorn ... a lung disease that afflicts people who work in the ... Publishing in the September issue of the American Journal ...
... smoking are more likely to have sleep disturbances such ... sleep duration, and snoring loudly or breathing uncomfortably, according ... of the journal SLEEP. , The study, authored by ... focused on the responses of 16,396 and 19,386 pregnant ...
Cached Medicine News:Health News:High and mighty: first common height gene identified by researchers behind 'obesity gene' finding 2Health News:High and mighty: first common height gene identified by researchers behind 'obesity gene' finding 3Health News:Two studies published in the Lancet 2Health News:Novel 3-D cell culture model shows selective tumour uptake of nanoparticles 2Health News:Scientists ID Likely Culprit in 'Popcorn Lung' 2Health News:Passive smoking increases sleep disturbance among pregnant women 2
Plastic Citrate Tube, .109M / 3.2%...
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
Inquire...
... EDTA K2 / gel tubes are ... for molecular diagnostics and for viral ... whole blood remain stable at room ... For optimal results, it is recommended ...
Medicine Products: